Globus Medical (GMED) CFO receives grant of 30,000 stock options

Rhea-AI Filing Summary

Globus Medical Senior Vice President and CFO Kyle Kline received a grant of 30,000 stock options to buy Class A common stock at an exercise price of $94.15 per share. The options were granted on January 21, 2026 and were reported as directly owned by Kline. They vest over a four-year period, with one-quarter vesting on January 1, 2027 and the remaining three-quarters vesting in equal monthly installments of 1/48 of the grant each month thereafter, ending on the stated expiration date of January 21, 2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kline Kyle

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$94.15	01/21/2026		A		30,000		(1)	01/21/2036	Class A Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. These options were granted on January 21, 2026, and vest over a four-year period with 1/4 of the options vesting on January 1, 2027, and then 1/48 of the options vesting each month thereafter.

	/s/ Kelly G. Huller, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Globus Medical (GMED) disclose about Kyle Kline in this Form 4?

The filing shows that Kyle Kline, Globus Medical's Senior Vice President and CFO, received a grant of 30,000 stock options for Class A common stock on January 21, 2026.

What are the key terms of Kyle Kline's new stock options at Globus Medical (GMED)?

The options are for 30,000 shares of Class A common stock with an exercise price of $94.15 per share, expiring on January 21, 2036, and were acquired at a price of $0 for the derivative itself.

How do Kyle Kline's Globus Medical (GMED) stock options vest?

The options vest over four years: 1/4 of the grant vests on January 1, 2027, and the remaining 1/48 of the grant vests each month thereafter until fully vested.

How many Globus Medical (GMED) stock options does Kyle Kline hold after this transaction?

After this grant, Kline beneficially owns 30,000 stock options related to Globus Medical Class A common stock, reported as held in direct ownership.

Is this Globus Medical (GMED) Form 4 about a purchase or sale of common shares?

No, the Form 4 reports the grant of stock options, a derivative security giving the right to buy Class A common stock at $94.15 per share, rather than a direct purchase or sale of common shares.